MeSH

A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)

A pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of TYPE 2 DIABETES.

Year introduced: 2016 (2008)

a combination of metformin and rosiglitazone used for treating type 2 diabetes

Date introduced: February 12, 2003

structure in first source

Date introduced: November 3, 1997

Glyburide/metformin (Glucovance) for type 2 diabetes

Date introduced: December 26, 2000

a combination of metformin, glutamate, and docosahexaenoic acid; has antidiabetic activity; structure in first source

Date introduced: November 5, 2017

A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)

fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes

Date introduced: January 13, 2014

a plant gum from Detarium microcarpum; made up of largely D-galactose as the major monosccharide with some quantities of D-mannose and D-glucose; a good excipient for the formulation of metformin mucoadhesive delivery systems

Date introduced: October 7, 2004

An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

Year introduced: 2016 (2001)